Literature DB >> 18791332

Human fetal striatal transplantation in huntington's disease: a refinement of the stereotactic procedure.

Pasquale Gallina1, Marco Paganini, Andrea Di Rita, Letizia Lombardini, Marco Moretti, Gabriella Barbara Vannelli, Nicola Di Lorenzo.   

Abstract

BACKGROUND: Human fetal striatal transplantation (HFST) is an experimental stereotactic intervention in the treatment of Huntington's disease (HD). This procedure has proved feasible, safe, well tolerated and it offers a potential strategy for brain repair in HD patients. Target areas are the nucleus caudatus caput (NCc) and the precommissural and postcommissural putamen (Pu). A suboptimal spatial distribution of grafts was frequently reported, especially for the postcommissural Pu, because of striatal atrophy and the concurrent ventricular frontal horn enlargement. An improvement of the stereotactic procedure aimed to optimize the intrastriatal placement of grafts is therefore considered a timely issue.
METHODS: Eight consecutive HD patients underwent bilateral HFST. For the first 6 procedures (first group) we performed both caudate and putaminal tracks through a single frontal entry point. For the following 10 procedures (second group), we adopted two completely distinct routes, with two separate entry points, for NCc and Pu tracks. The average number of stereotactic tracks and the average infused volume of tissue suspension were compared between the two groups.
RESULTS: The average number of putaminal tracks and the average infused volume of suspension were significantly higher in the second group.
CONCLUSION: Adopting two separate routes for caudate and putaminal trajectories allowed us to achieve a larger amount of fetal tissue deposits and a better spatial distribution of grafts. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18791332     DOI: 10.1159/000155233

Source DB:  PubMed          Journal:  Stereotact Funct Neurosurg        ISSN: 1011-6125            Impact factor:   1.875


  6 in total

1.  Human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges.

Authors:  Camille Nicoleau; Pedro Viegas; Marc Peschanski; Anselme L Perrier
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

2.  Devices for cell transplantation into the central nervous system: Design considerations and emerging technologies.

Authors:  Matthew B Potts; Matthew T Silvestrini; Daniel A Lim
Journal:  Surg Neurol Int       Date:  2013-03-19

3.  Installation of a Neuromate Robot for Stereotactic Surgery: Efforts to Conform to Japanese Specifications and an Approach for Clinical Use-Technical Notes.

Authors:  Yasukazu Kajita; Daisuke Nakatsubo; Hirotada Kataoka; Toshiya Nagai; Takahiro Nakura; Toshihiko Wakabayashi
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-10-28       Impact factor: 1.742

4.  Functionalized carbon nanotubes in the brain: cellular internalization and neuroinflammatory responses.

Authors:  Giuseppe Bardi; Antonio Nunes; Lisa Gherardini; Katie Bates; Khuloud T Al-Jamal; Claire Gaillard; Maurizio Prato; Alberto Bianco; Tommaso Pizzorusso; Kostas Kostarelos
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

5.  Fetal striatal grafting slows motor and cognitive decline of Huntington's disease.

Authors:  Marco Paganini; Annibale Biggeri; Anna Maria Romoli; Claudia Mechi; Elena Ghelli; Valentina Berti; Silvia Pradella; Sandra Bucciantini; Dolores Catelan; Riccardo Saccardi; Letizia Lombardini; Mario Mascalchi; Luca Massacesi; Berardino Porfirio; Nicola Di Lorenzo; Gabriella Barbara Vannelli; Pasquale Gallina
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-12-17       Impact factor: 10.154

Review 6.  Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases?

Authors:  Cristina Salado-Manzano; Unai Perpiña; Marco Straccia; Francisco J Molina-Ruiz; Emanuele Cozzi; Anne E Rosser; Josep M Canals
Journal:  Front Cell Neurosci       Date:  2020-08-11       Impact factor: 6.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.